MSF's Suerie Moon spoke in front of a US Senate Committee on promoting new treatments & cures for neglected diseases read more
NEW: The 13th Edition of Untangling the Web of Antiretroviral Price Reductions is now available download it here
VIDEO: MSF's community approach to treating malnutrition in Niger watch it here
WHO's work on the financing of medical research and development is given a fresh start read more
MSF Letter to GFATM on concerns over scale-up of AIDS treatment in light of Board of Directors Meeting read more
New European Parliament Working Group on Innovation & Access launches with support of Access Campaign read more
|
 |
|
 |
|
Medicines Patent Pool clears last procedural hurdle and gets ready to open its doors Read more on the current status of Patent Pool discussions Learn how a Pool could work to boost access to HIV medicines.
|
MSF & the 63rd World Health Assembly
MSF shared its perspective on key issues related to access to medicines and medical innovation that will be discussed at the WHA. In particular: infant and young child nutrition; counterfeit medicinal products; and public health, innovation and intellectual property.
UPDATE: Learn more about the outcomes of EWG discussions, read "New direction: WHO's work on the financing of medical research and development is given a fresh start" (16 June 2010)
To learn more about what MSF is saying to this year's WHA, click here.
|
Free Trade Agreement (FTA) negotiations between India and the European Union threaten the critical role India plays in supplying affordable generic versions of drugs throughout the developing world. Learn more about how an FTA between India & the EU could impact access to medicines |
Brazil: Pipeline patents
Pipeline patents put the Brazilian commitment to provide universal access to AIDS treatment under severe strain by granting unjustified patents on medicines, shutting out generic competition and keeping the price of drugs high.
But in a case with far-reaching consequences, the Supreme Court is looking at whether this measure is constitutional or not. Find out what MSF thinks about it.
Meet the Activist: Leena Menghaney
Leena Menghaney is a lawyer by training and works for the Access Campaign in New Delhi. Currently she is working with other civil society groups on patent oppositions to newer HIV drugs Read more |
Patent Disputes
India's role as ‘pharmacy to the developing world’ is under attack
Right now a number of multinational drug companies, such as Bayer and Novartis, are trying to shut down competition from generic drug makers by attacking India’s patent laws in the courts.
To learn more about current cases in India and to hear interviews with Access team members in the region, click here.
|
Director of Policy and Advocacy Michelle Childs noted concerns on the executive summary of the Expert Working Group Report on R&D Financing at the WHO Executive Board. Childs urged members to take a pro-health focus on priority setting, R&D funding, and IP management. Read more |
|
Thailand issued compulsory licenses on AIDS drugs in order to be able to treat more patients. Hear Dr.Suwit Wibulpolprasert of the Thai Ministry of Public Health talk about the experience |
Counterfeit, substandard and generic drugs: the need for clarity
MSF is faced with the problem of medicines that do not meet quality standards.
Read what we propose to improve the situation. 
Confusing counterfeit, substandard and generic medicines can have serious repercussions on access to medicines.
Ellen ‘t Hoen, former Policy Director at MSF, explains why.
The lack of clarity around what constitutes a counterfeit medicine in a new Kenyan law could harm access to essential medicines.
|
Ellen 't Hoen, former Director of Policy at the MSF Access Campaign, launches her book, The Global Politics of Pharmaceutical Monopoly Power - Drug patents, access, innovation and the application of the WTO Doha Declaration on TRIPS and Public Health. Read more and download the book. |
|
FATAL FLAWS: How Kenya's 2008 Anti-Counterfeit Act could endanger access to medicines 
Presenation: Missing ARVs for HIV/AIDS treatment in 2009 - Unitaid Patent Pool Briefing
HIV/AIDS treatment in developing countries: the battle for long-term survival has just begun
